| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
|
N Engl J Med
|
2011
|
28.99
|
|
2
|
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
|
N Engl J Med
|
2003
|
6.70
|
|
3
|
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
|
Chest
|
2012
|
5.27
|
|
4
|
A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study.
|
J Am Coll Cardiol
|
2011
|
5.06
|
|
5
|
The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators.
|
N Engl J Med
|
1990
|
4.77
|
|
6
|
Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?
|
JAMA
|
2003
|
4.13
|
|
7
|
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
|
Circulation
|
2012
|
4.10
|
|
8
|
Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators.
|
Stroke
|
2009
|
3.89
|
|
9
|
Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study.
|
Arch Intern Med
|
2002
|
3.78
|
|
10
|
Long-term outcomes of surgical and nonsurgical management of lumbar spinal stenosis: 8 to 10 year results from the maine lumbar spine study.
|
Spine (Phila Pa 1976)
|
2005
|
3.67
|
|
11
|
Mortality among homeless adults in Boston: shifts in causes of death over a 15-year period.
|
JAMA Intern Med
|
2013
|
3.67
|
|
12
|
The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage.
|
Arch Intern Med
|
2004
|
3.63
|
|
13
|
A controlled trial of web-based diabetes disease management: the MGH diabetes primary care improvement project.
|
Diabetes Care
|
2003
|
3.57
|
|
14
|
Long-term outcomes of surgical and nonsurgical management of sciatica secondary to a lumbar disc herniation: 10 year results from the maine lumbar spine study.
|
Spine (Phila Pa 1976)
|
2005
|
3.17
|
|
15
|
Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis.
|
Stroke
|
2003
|
3.12
|
|
16
|
Tests of glycemia for the diagnosis of type 2 diabetes mellitus.
|
Ann Intern Med
|
2002
|
3.06
|
|
17
|
Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation.
|
Ann Intern Med
|
2004
|
3.06
|
|
18
|
Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis.
|
JAMA
|
2002
|
2.94
|
|
19
|
Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation.
|
J Am Coll Cardiol
|
2008
|
2.93
|
|
20
|
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF.
|
Lancet Neurol
|
2012
|
2.77
|
|
21
|
The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study.
|
Circ Arrhythm Electrophysiol
|
2009
|
2.59
|
|
22
|
The unmet health care needs of homeless adults: a national study.
|
Am J Public Health
|
2010
|
2.36
|
|
23
|
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.
|
Eur Heart J
|
2011
|
2.31
|
|
24
|
Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population.
|
Am J Cardiol
|
2013
|
2.29
|
|
25
|
Comparison of hyperglycemia, hypertension, and hypercholesterolemia management in patients with type 2 diabetes.
|
Am J Med
|
2002
|
2.19
|
|
26
|
Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study.
|
Circulation
|
2009
|
2.18
|
|
27
|
Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation.
|
Circ Cardiovasc Qual Outcomes
|
2010
|
2.17
|
|
28
|
Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
|
J Am Coll Cardiol
|
2013
|
2.17
|
|
29
|
Death and disability from warfarin-associated intracranial and extracranial hemorrhages.
|
Am J Med
|
2007
|
2.16
|
|
30
|
Trends in complexity of diabetes care in the United States from 1991 to 2000.
|
Arch Intern Med
|
2004
|
2.06
|
|
31
|
Polypharmacy and medication adherence in patients with type 2 diabetes.
|
Diabetes Care
|
2003
|
2.00
|
|
32
|
National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation.
|
Arch Intern Med
|
2004
|
1.92
|
|
33
|
Are patients more likely to see physicians of the same sex? Recent national trends in primary care medicine.
|
Am J Med
|
2004
|
1.87
|
|
34
|
A controlled trial of population management: diabetes mellitus: putting evidence into practice (DM-PEP).
|
Diabetes Care
|
2004
|
1.85
|
|
35
|
Incidence of newly detected atrial arrhythmias via implantable devices in patients with a history of thromboembolic events.
|
Stroke
|
2009
|
1.81
|
|
36
|
Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria.
|
Am J Respir Crit Care Med
|
2002
|
1.78
|
|
37
|
Protecting an endangered species: training physicians to conduct clinical research.
|
Acad Med
|
2009
|
1.66
|
|
38
|
Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study.
|
Circulation
|
2005
|
1.66
|
|
39
|
Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry.
|
Circulation
|
2013
|
1.63
|
|
40
|
Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia.
|
Arch Intern Med
|
2002
|
1.57
|
|
41
|
Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF).
|
Circulation
|
2014
|
1.54
|
|
42
|
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial.
|
Eur Heart J
|
2013
|
1.53
|
|
43
|
Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study.
|
J Am Geriatr Soc
|
2006
|
1.51
|
|
44
|
Warfarin discontinuation after starting warfarin for atrial fibrillation.
|
Circ Cardiovasc Qual Outcomes
|
2010
|
1.39
|
|
45
|
Food insufficiency and health services utilization in a national sample of homeless adults.
|
J Gen Intern Med
|
2011
|
1.38
|
|
46
|
Depressive symptom burden as a barrier to screening for breast and cervical cancers.
|
J Womens Health (Larchmt)
|
2004
|
1.28
|
|
47
|
Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial.
|
J Am Coll Cardiol
|
2013
|
1.23
|
|
48
|
Desire for antibiotics and antibiotic prescribing for adults with upper respiratory tract infections.
|
J Gen Intern Med
|
2003
|
1.23
|
|
49
|
Factor V Leiden and risk of ischemic stroke in nonvalvular atrial fibrillation: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.
|
J Thromb Thrombolysis
|
2003
|
1.20
|
|
50
|
Device-detected atrial fibrillation and risk for stroke: an analysis of >10,000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices).
|
Eur Heart J
|
2013
|
1.17
|
|
51
|
Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation.
|
J Am Heart Assoc
|
2013
|
1.15
|
|
52
|
The effect of surgical and nonsurgical treatment on longitudinal outcomes of lumbar spinal stenosis over 10 years.
|
J Am Geriatr Soc
|
2005
|
1.13
|
|
53
|
Bupropion for smokers hospitalized with acute cardiovascular disease.
|
Am J Med
|
2006
|
1.13
|
|
54
|
The impact of disability compensation on long-term treatment outcomes of patients with sciatica due to a lumbar disc herniation.
|
Spine (Phila Pa 1976)
|
2006
|
1.11
|
|
55
|
Community-acquired pneumonia and do not resuscitate orders.
|
J Am Geriatr Soc
|
2002
|
1.10
|
|
56
|
Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants.
|
Stroke
|
2012
|
1.10
|
|
57
|
Improving adherence and reducing medication discrepancies in patients with diabetes.
|
Ann Pharmacother
|
2003
|
1.06
|
|
58
|
Impact of concurrent medication use on statin adherence and refill persistence.
|
Arch Intern Med
|
2004
|
1.05
|
|
59
|
Measures of health-related quality of life for adults with acute sinusitis. A systematic review.
|
J Gen Intern Med
|
2003
|
1.03
|
|
60
|
Tobacco-, alcohol-, and drug-attributable deaths and their contribution to mortality disparities in a cohort of homeless adults in Boston.
|
Am J Public Health
|
2014
|
1.02
|
|
61
|
Outcomes in lower respiratory tract infections and the impact of antimicrobial drug resistance.
|
Clin Microbiol Infect
|
2002
|
1.02
|
|
62
|
Association between antibiotic prescribing and visit duration in adults with upper respiratory tract infections.
|
Clin Ther
|
2003
|
1.02
|
|
63
|
Methodologic problems in the assessment of bleed scores.
|
J Am Coll Cardiol
|
2013
|
1.01
|
|
64
|
Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation.
|
Am Heart J
|
2009
|
1.00
|
|
65
|
Frequent outpatient contact and decreasing medication affordability in patients with diabetes from 1997 to 2004.
|
Diabetes Care
|
2006
|
1.00
|
|
66
|
Detection of previously undiagnosed atrial fibrillation in patients with stroke risk factors and usefulness of continuous monitoring in primary stroke prevention.
|
Am J Cardiol
|
2012
|
0.98
|
|
67
|
Validity of a new health-related quality of life instrument for patients with chronic sinusitis.
|
Laryngoscope
|
2005
|
0.97
|
|
68
|
Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.
|
Circ Cardiovasc Qual Outcomes
|
2013
|
0.97
|
|
69
|
Health care resource utilization associated with a diabetes center and a general medicine clinic.
|
J Gen Intern Med
|
2004
|
0.95
|
|
70
|
Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation.
|
Stroke
|
2014
|
0.94
|
|
71
|
Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF.
|
Circ Heart Fail
|
2013
|
0.93
|
|
72
|
Anticoagulation therapy for patients with non-valvular atrial fibrillation: comparison of decision analytic model recommendations and real-world warfarin prescription use.
|
Am J Cardiovasc Drugs
|
2012
|
0.92
|
|
73
|
The Maine-Seattle back questionnaire: a 12-item disability questionnaire for evaluating patients with lumbar sciatica or stenosis: results of a derivation and validation cohort analysis.
|
Spine (Phila Pa 1976)
|
2003
|
0.89
|
|
74
|
Medication adherence before an increase in antihypertensive therapy: a cohort study using pharmacy claims data.
|
Clin Ther
|
2005
|
0.89
|
|
75
|
Rationale and design of a prospective study of the clinical significance of atrial arrhythmias detected by implanted device diagnostics: the TRENDS study.
|
J Interv Card Electrophysiol
|
2006
|
0.89
|
|
76
|
Stroke prevention in atrial fibrillation in older adults: existing knowledge gaps and areas for innovation: a summary of an American Federation for Aging research seminar.
|
J Am Geriatr Soc
|
2013
|
0.88
|
|
77
|
Development and validation of a new health-related quality of life instrument for patients with sinusitis.
|
Qual Life Res
|
2005
|
0.87
|
|
78
|
Challenges to the effective use of unfractionated heparin in the hospitalized management of acute thrombosis.
|
Arch Intern Med
|
2003
|
0.87
|
|
79
|
Comparative effectiveness of post-discharge interventions for hospitalized smokers: study protocol for a randomized controlled trial.
|
Trials
|
2012
|
0.86
|
|
80
|
Evaluating area-based socioeconomic status indicators for monitoring disparities within health care systems: results from a primary care network.
|
Health Serv Res
|
2014
|
0.86
|
|
81
|
Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
|
Ann Intern Med
|
2013
|
0.86
|
|
82
|
Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial.
|
J Am Heart Assoc
|
2014
|
0.85
|
|
83
|
End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience.
|
Circ Cardiovasc Qual Outcomes
|
2013
|
0.83
|
|
84
|
Long-term survival after ischemic stroke in patients with atrial fibrillation.
|
Neurology
|
2014
|
0.83
|
|
85
|
Limited English proficient patients and time spent in therapeutic range in a warfarin anticoagulation clinic.
|
J Am Heart Assoc
|
2013
|
0.83
|
|
86
|
Health-related quality of life of adults with upper respiratory tract infections.
|
J Gen Intern Med
|
2003
|
0.81
|
|
87
|
Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF.
|
Eur Heart J
|
2013
|
0.79
|
|
88
|
A new era in stroke prevention for atrial fibrillation: comment on "current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation.
|
Arch Intern Med
|
2012
|
0.78
|
|
89
|
Response to letter regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts".
|
Circulation
|
2013
|
0.77
|
|
90
|
CHA2DS2-VASc risk scheme: not ready for clinical use.
|
Chest
|
2010
|
0.76
|
|
91
|
Putting risk prediction in atrial fibrillation into perspective.
|
Eur Heart J
|
2012
|
0.75
|
|
92
|
The international normalized ratio range of 2.0 to 3.0 remains appropriate for atrial fibrillation.
|
Arch Intern Med
|
2009
|
0.75
|
|
93
|
Stroke prevention in atrial fibrillation: another step sideways.
|
Lancet
|
2008
|
0.75
|
|
94
|
Reply: Comparing the ATRIA, CHADS2, and CHA2DS2-VASc Scores for Stroke Prediction in Atrial Fibrillation.
|
J Am Coll Cardiol
|
2016
|
0.75
|
|
95
|
Can Text Messages Improve Attendance to Primary Care Appointments in Underserved Populations?
|
J Health Care Poor Underserved
|
2016
|
0.75
|
|
96
|
An instrument for determining the amount of NIH support for clinical investigations at one academic health center.
|
Acad Med
|
2002
|
0.75
|
|
97
|
RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate.
|
Thromb Haemost
|
2016
|
0.75
|
|
98
|
Antithrombotic therapy for stroke prevention in atrial fibrillation.
|
Prog Cardiovasc Dis
|
2005
|
0.75
|
|
99
|
First Diagnosis of Atrial Fibrillation at the Time of Stroke.
|
Cerebrovasc Dis
|
2017
|
0.75
|
|
100
|
Anticoagulation for atrial fibrillation.
|
Cardiol Clin
|
2004
|
0.75
|
|
101
|
Reply: Recent Diabetes and Atrial Fibrillation Report Diverges From Pre-Existing Evidence.
|
J Am Coll Cardiol
|
2016
|
0.75
|
|
102
|
Oral anticoagulants vs. aspirin for stroke prevention in patients with non-valvular atrial fibrillation: the verdict is in.
|
Card Electrophysiol Rev
|
2003
|
0.75
|